1.0Market Newsdeskhttps://www.marketnewsdesk.comNewsdeskhttps://www.marketnewsdesk.com/index.php/author/newsdesk/rich600338<blockquote class="wp-embedded-content" data-secret="wDB2RSKRjR"><a href="https://www.marketnewsdesk.com/index.php/organovo-provides-business-update/">Organovo Provides Business Update</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://www.marketnewsdesk.com/index.php/organovo-provides-business-update/embed/#?secret=wDB2RSKRjR" width="600" height="338" title="“Organovo Provides Business Update” — Market Newsdesk" data-secret="wDB2RSKRjR" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); //# sourceURL=https://www.marketnewsdesk.com/wp-includes/js/wp-embed.min.js </script> SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today provided a business update. With the closing of the sale of its FXR Program to Lilly (NYSE:LLY), Organovo has received upfront payments and anticipates future milestone payments. When combined with funding from previously reported warrant exercises and additional monies raised through equity sales, the company believes it is well-positioned to repeat the FXR314 success with another IBD opportunity. The company expects an overall decrease in expenditures in the coming year, due to the elimination of costs related to pushing FXR314 into and through the clinic, as well … Continue reading ""https://www.globenewswire.com/newsroom/ti?nf=OTQxMTkyMyM2ODM3MTc0IzIwMjAwODU=